Provectus Biopharmaceuticals Announces Acceptance of PV-10 Poster Presentations at Society for Melanoma Research (SMR) 2023 Congress KNOXVILLE, TN, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from ongoing clinical trials of investigational cancer immunotherapy PV-10 (rose bengal sodium) for...

Morphic Presents Preclinical Data from αvβ8 Integrin Program at the SITC Annual Meeting αvβ8 inhibition demonstrates efficacy in a cancer model refractory to radiation and checkpoint inhibition Data provide increased rationale to explore integrin inhibition as a component in combination...

Morphic Therapeutic Presents Preclinical Data from αvβ8 Integrin Program at American Association for Cancer Research (AACR) Annual Meeting First data from oral αvβ8 program demonstrate potent anti-tumor response through TGFβ pathway Combination with checkpoint inhibitor showed efficacy in checkpoint-resistant models of breast cancer and...